ZA200609140B - Use of IL-17 expression to predict skin inflammation ; methods of treatment - Google Patents

Use of IL-17 expression to predict skin inflammation ; methods of treatment

Info

Publication number
ZA200609140B
ZA200609140B ZA200609140A ZA200609140A ZA200609140B ZA 200609140 B ZA200609140 B ZA 200609140B ZA 200609140 A ZA200609140 A ZA 200609140A ZA 200609140 A ZA200609140 A ZA 200609140A ZA 200609140 B ZA200609140 B ZA 200609140B
Authority
ZA
South Africa
Prior art keywords
expression
treatment
methods
skin inflammation
predict skin
Prior art date
Application number
ZA200609140A
Other languages
English (en)
Inventor
Robert A Kastelein
Murphy Erin
Terrill K Mcclanahan
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ZA200609140B publication Critical patent/ZA200609140B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ZA200609140A 2004-05-03 2006-11-02 Use of IL-17 expression to predict skin inflammation ; methods of treatment ZA200609140B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56774704P 2004-05-03 2004-05-03

Publications (1)

Publication Number Publication Date
ZA200609140B true ZA200609140B (en) 2007-11-28

Family

ID=34967584

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200609140A ZA200609140B (en) 2004-05-03 2006-11-02 Use of IL-17 expression to predict skin inflammation ; methods of treatment

Country Status (11)

Country Link
US (2) US7501247B2 (ja)
EP (1) EP1761643A1 (ja)
JP (1) JP2007535930A (ja)
CN (1) CN1993480A (ja)
AU (1) AU2005241020B2 (ja)
BR (1) BRPI0510617A (ja)
CA (1) CA2565566A1 (ja)
MX (1) MXPA06012754A (ja)
NO (1) NO20065560L (ja)
WO (1) WO2005108616A1 (ja)
ZA (1) ZA200609140B (ja)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7422743B2 (en) * 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
US20070160576A1 (en) * 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
DE60328823D1 (de) 2002-10-30 2009-09-24 Genentech Inc Hemmung von il-17 produktion
EP1623011B1 (en) * 2003-05-09 2013-01-02 Janssen Biotech, Inc. Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
US7501247B2 (en) * 2004-05-03 2009-03-10 Schering Corporation Method of treating skin inflammation
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
EP1671642A1 (en) * 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
JP2008532493A (ja) * 2005-02-14 2008-08-21 ワイス Il−17fとil−17rとの間の相互作用の特性解析
PT2452694T (pt) * 2005-06-30 2019-02-21 Janssen Biotech Inc Anticorpos anti-il-23, composições, métodos e utilizações
EP2116258A1 (en) * 2005-09-01 2009-11-11 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
KR101210395B1 (ko) * 2005-12-29 2012-12-11 얀센 바이오테크 인코포레이티드 인간 항-il-23 항체, 조성물, 방법 및 용도
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
JP2009541338A (ja) * 2006-06-19 2009-11-26 ワイス Il−22およびil−17の調節方法
PE20080739A1 (es) 2006-08-11 2008-06-14 Schering Corp Anticuerpos para il-17a
CN101668531B (zh) * 2007-02-28 2014-05-07 默沙东公司 用于治疗免疫病症的联合治疗
EP2150564A2 (en) * 2007-04-27 2010-02-10 ZymoGenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
CA2721713C (en) 2008-05-05 2019-07-09 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
AU2009246180B2 (en) 2008-05-14 2015-11-05 Dermtech International Diagnosis of melanoma and solar lentigo by nucleic acid analysis
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
CN102449170A (zh) * 2009-04-15 2012-05-09 西北大学 寡核苷酸功能化的纳米颗粒的递送
MX2011011729A (es) 2009-05-05 2012-04-10 Novimmune Sa Anticuerpo anti il-17f y metodos de uso de los mismos.
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
WO2011053763A2 (en) 2009-10-30 2011-05-05 Centocor Ortho Biotech Inc. Il-17a antagonists
EP3456740A1 (en) 2010-11-04 2019-03-20 Boehringer Ingelheim International GmbH Anti-il-23 antibodies
JP6279467B2 (ja) 2011-06-27 2018-02-14 ガルデルマ・リサーチ・アンド・デヴェロップメント ざ瘡についての新規th17分化マーカーおよびその使用
WO2013116682A1 (en) 2012-02-02 2013-08-08 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
EA201401204A1 (ru) 2012-05-03 2015-05-29 Бёрингер Ингельхайм Интернациональ Гмбх Антитела к il-23p19
US9708401B2 (en) 2012-05-22 2017-07-18 Bristol-Myers Squibb Company IL-17A/F cross-reactive monoclonal antibodies and methods of using the same
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
KR102523914B1 (ko) 2014-09-03 2023-04-19 베링거잉겔하임인터내쇼날유한회사 Il-23a 및 tnf-알파를 표적으로 하는 화합물 및 이의 용도
CN107849128A (zh) * 2015-07-16 2018-03-27 伊莱利利公司 瘙痒治疗
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
CN109415731A (zh) 2016-05-06 2019-03-01 埃克西奎雷股份有限公司 呈递用于特异性敲低白介素17受体mRNA的反义寡核苷酸(ASO)的脂质体球形核酸(SNA)构建体
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
AU2019222462A1 (en) 2018-02-14 2020-09-03 Dermtech, Inc. Novel gene classifiers and uses thereof in non-melanoma skin cancers
AU2019266226A1 (en) 2018-05-09 2020-12-03 Dermtech, Inc. Novel gene classifiers and uses thereof in autoimmune diseases
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
EP1076703B2 (en) 1998-05-15 2010-12-15 Genentech, Inc. Therapeutic uses of il-17 homologous polypeptides
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7090847B1 (en) * 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
DK1240325T3 (da) 1999-12-23 2010-01-25 Genentech Inc IL-17 og IL-17R homologe polypeptider og terapeutisk anvendelse deraf
JP2003527104A (ja) * 1999-12-23 2003-09-16 ジェネンテック・インコーポレーテッド Il−17相同的ポリペプチドとその治療上の用途
NZ522146A (en) * 2000-05-10 2004-10-29 Schering Corp Mammalian receptor-like proteins, designated DNAX cytokine receptor subunits (DCRS), in particular DCRS5
EP2366406A1 (en) 2001-01-25 2011-09-21 ZymoGenetics, Inc. Method for treating psoriasis
US20020169127A1 (en) 2001-03-29 2002-11-14 Charmley Patrick R. Compositions and methods for diagnosing or treating psoriasis
DE60328823D1 (de) * 2002-10-30 2009-09-24 Genentech Inc Hemmung von il-17 produktion
WO2004058178A2 (en) * 2002-12-23 2004-07-15 Schering Corporation Uses of mammalian cytokine; related reagents
CA2511838C (en) 2002-12-31 2014-05-06 Schering Corporation Uses of mammalian cytokine; related reagents
EP1623011B1 (en) * 2003-05-09 2013-01-02 Janssen Biotech, Inc. Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
KR100945327B1 (ko) 2003-07-08 2010-03-08 제넨테크, 인크. Il-17a/f 이종 폴리펩티드 및 그의 치료 용도
US7501427B2 (en) * 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US7183057B2 (en) * 2004-03-31 2007-02-27 Dermtech International Tape stripping methods for analysis of skin disease and pathological skin state
US20050287593A1 (en) * 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
US7501247B2 (en) * 2004-05-03 2009-03-10 Schering Corporation Method of treating skin inflammation

Also Published As

Publication number Publication date
WO2005108616A1 (en) 2005-11-17
US20090028860A1 (en) 2009-01-29
JP2007535930A (ja) 2007-12-13
CN1993480A (zh) 2007-07-04
US7501247B2 (en) 2009-03-10
AU2005241020B2 (en) 2008-07-10
US20050244874A1 (en) 2005-11-03
MXPA06012754A (es) 2007-02-19
BRPI0510617A (pt) 2007-10-30
CA2565566A1 (en) 2005-11-17
US7776540B2 (en) 2010-08-17
EP1761643A1 (en) 2007-03-14
NO20065560L (no) 2006-12-01
AU2005241020A1 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
ZA200609140B (en) Use of IL-17 expression to predict skin inflammation ; methods of treatment
IL263237A (en) Use of complement pathway inhibitors to treat eye diseases
HK1250781A1 (zh) 在診斷和治療炎性疾病上凝溶膠蛋白的應用
EP1755661A4 (en) USE OF GELSOLINE FOR THE TREATMENT OF INFECTIONS
GB0610867D0 (en) Treatment of pain
IL176960A0 (en) Compositions and methods of treatment for inflammatory diseases
EP1766086A4 (en) USE OF GENETIC EXPRESSION PROFILING TO PREVENT THE CHANCE OF SURVIVAL OF A PATIENT WITH CANCER
EP1933880A4 (en) OLIGORIBONUCLEOTIDES AND METHODS OF USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES
EP1804813A4 (en) FORMULATIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
HK1109062A1 (en) Compositions and methods of use for treatment of mammalian diseases
EP1838714A4 (en) METHODS OF TREATING PAIN
IL189972A0 (en) Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
IL193748A0 (en) Treatment of pain
EP2155225A4 (en) METHODS OF TREATING SKIN ULCERS
PT2254869T (pt) Novos derivados de 1-benzil-3-hidroximetilindazole e suas utilizações no tratamento de doenças com base na expressão de cx3cr1 e p40
EP2063859A4 (en) COSMETIC COMPOSITION FOR SKIN TREATMENT AND RELATED METHODS
EP2021005A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF INFLAMMATORY PAIN
GB0610868D0 (en) Treatment of pain
PL1818064T3 (pl) Sposoby traktowania skóry w celu wzmocnienia jej leczenia terapeutycznego
GB0526394D0 (en) Treatment of inflammatory diseases
EP1718329A4 (en) METHOD FOR THE TREATMENT OF SKIN DISEASES
EP1846013A4 (en) TREATMENT OF SKIN DISEASES
GB0616450D0 (en) Treatment of pain
IL182987A0 (en) Treatment of inflammation
GB0411302D0 (en) Treatment of inflammatory diseases